Actively Recruiting

Phase 1
Age: 0Days - 9Months
All Genders
NCT06700811

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Led by Heather Olson · Updated on 2026-02-02

10

Participants Needed

1

Research Sites

142 weeks

Total Duration

On this page

Sponsors

H

Heather Olson

Lead Sponsor

B

Boston Children's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

Epileptic spasms (ES) are a predominantly infantile seizure type observed frequently in certain genetic disorders. Ketogenic diet (high ratio of fat to carbohydrate/protein) is an established non-medication treatment for difficult to control seizures, including ES. Because ES are associated with worse developmental and cognitive outcomes if not detected or treated quickly and effectively, this trial aims to test the ketogenic diet to prevent ES in this high-risk population. This trial is a single-center pilot study of 10 infants with genetic seizure disorders to establish if the protocol of early ketogenic diet administration and ES evaluation is safe and feasible.

CONDITIONS

Official Title

Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies

Who Can Participate

Age: 0Days - 9Months
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Plan for initiation of ketogenic diet by clinical team for treatment of epilepsy
  • The clinical team agrees that the KetoVie formula is appropriate for the subject
  • Male or female, age 0 to less than 9 months (including neonates per investigator's judgment)
  • Epilepsy onset at less than 6 months of age
  • Abnormal development and/or abnormal neurologic exam per investigator's judgment
  • Genetic epilepsy diagnosis with pathogenic or likely pathogenic variant(s) consistent with phenotype and inheritance
  • Weight adequate to complete study laboratory testing without exceeding blood draw limits per BCH policy
Not Eligible

You will not qualify if you...

  • Epileptic spasms prior to enrollment
  • Diagnosis of tuberous sclerosis complex or trisomy 21
  • Metabolic diagnosis with targeted treatment or exclusion for ketogenic diet
  • Ongoing treatment with vigabatrin, ACTH, corticosteroids, topiramate, or zonisamide

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Boston Children's Hospital

Boston, Massachusetts, United States, 02115

Actively Recruiting

Loading map...

Research Team

H

Heather E Olson, MD, MS

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

PREVENTION

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here